

Overview

Useful For

Determining whether a patient has had previous exposure to or recent infection with *Toxoplasma gondii*

Highlights

Detection of IgM-class antibodies to *Toxoplasma gondii* may be useful as a screen for recent infection with *Toxoplasma gondii*.

Per the FDA, IgM-positive results by a screening assay should be confirmed, for example by a *Toxoplasma* reference laboratory.

A single negative result by this assay does not rule-out toxoplasmosis as the specimen may have been collected too early following infection, prior to development of detectable antibodies.

A single IgG-positive result is indicative of exposure to *Toxoplasma gondii* at some time in the past.

Profile Information

Test ID	Reporting Name	Available Separately	Always Performed
TXM	Toxoplasma Ab, IgM, S	Yes	Yes
TOXGP	Toxoplasma Ab, IgG, S	Yes	Yes

Testing Algorithm

See [Meningitis/Encephalitis Panel Algorithm](#) in Special Instructions.

Special Instructions

- [Meningitis/Encephalitis Panel Algorithm](#)

Method Name

Multiplex Flow Immunoassay (MFI)

NY State Available

Yes

Specimen

Specimen Type

Serum

Specimen Required

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Aliquot tube

Specimen Volume: 1.5 mL

Forms

If not ordering electronically, complete, print, and send a [Microbiology Test Request](#) (T244) with the specimen.

Specimen Minimum Volume

1.2 mL

Reject Due To

Gross hemolysis	Reject
Gross lipemia	Reject
Other	Heat-inactivated specimen

Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Serum	Refrigerated (preferred)	14 days	
	Frozen	14 days	

Clinical and Interpretive

Clinical Information

Toxoplasma gondii is an obligate intracellular protozoan parasite that is capable of infecting a variety of intermediate hosts including humans. Infected definitive hosts (cats) shed oocysts in feces that rapidly mature in the soil and become infectious. Toxoplasmosis is acquired by humans through ingestion of food or water contaminated with cat feces or through eating undercooked meat containing viable oocysts. Vertical transmission of the parasite through the placenta can also occur, leading to congenital toxoplasmosis. Following primary infection, *Toxoplasma gondii* can remain latent for the life of the host; the risk for reactivation is highest among immunosuppressed individuals.

Seroprevalence studies performed in the United States indicate that approximately 6.7% of individuals between the ages of 12 and 49 have antibodies to *Toxoplasma gondii*.

Infection of immunocompetent adults is typically asymptomatic. In symptomatic cases, patients most commonly present with lymphadenopathy and other nonspecific constitutional symptoms, making definitive diagnosis difficult to determine.

Severe-to-fatal infections can occur among patients with AIDS or individuals who are otherwise immunosuppressed. These infections are thought to be caused by reactivation of latent infections and commonly involved the central nervous system.

Transplacental transmission of the parasites resulting in congenital toxoplasmosis can occur during the acute phase of acquired maternal infection. The risk of fetal infection is a function of the time at which acute maternal infection occurs during gestation. The incidence of congenital toxoplasmosis increases as pregnancy progresses; conversely, the severity of congenital toxoplasmosis is greatest when maternal infection is acquired early during pregnancy. A

majority of infants infected in utero are asymptomatic at birth, particularly if maternal infection occurs during the third trimester, with sequelae appearing later in life. Congenital toxoplasmosis results in severe generalized or neurologic disease in about 20% to 30% of the infants infected in utero; approximately 10% exhibit ocular involvement only and the remainder are asymptomatic at birth. Subclinical infection may result in premature delivery and subsequent neurologic, intellectual, and audiologic defects.

Reference Values

Toxoplasma IgM

Negative

Toxoplasma IgG

Negative

Toxoplasma IgG Value

< or =9 IU/mL (Negative)

10-11 IU/mL (Equivocal)

> or =12 IU/mL (Positive)

Reference values apply to all ages.

Interpretation

Active toxoplasmosis is suggested by the presence of IgM-class antibodies, but elevated anti-IgM titers may be absent in immunocompromised patients. In addition, elevated IgM can persist from an acute infection that may have occurred as long ago as 1 year. A suspected diagnosis of acute toxoplasmosis should be confirmed by detection of *Toxoplasma gondii* DNA by PCR analysis of cerebrospinal fluid or amniotic fluid specimens (PTOX / *Toxoplasma gondii*, Molecular Detection, PCR).

For confirmation of toxoplasmosis, the FDA issued a Public Health Advisory (7/25/1997) that recommends that sera found to be positive for *Toxoplasma gondii* IgM antibodies should be sent to a *Toxoplasma* reference laboratory.

A single negative result should not be used to rule-out toxoplasmosis and repeat testing is recommended for patients at high risk for infection.

IgG is only indicative of previous exposure to *Toxoplasma* (recent or past). A single positive *Toxoplasma* IgG result should not be used to diagnose recent infection. Seroconversion from negative to positive IgG is indicative of recent *Toxoplasma gondii* infection.

Cautions

Diagnosis of recent infection by *Toxoplasma gondii* can only be established by a combination of clinical and serological data.

The result of a single serum sample does not constitute sufficient proof for diagnosis of recent infection. If a serum sample was collected too soon after infection, IgM antibodies to *Toxoplasma gondii* may be absent. If this is suspected, a second serum sample should be collected 2 to 3 weeks later and the test repeated.

Sera drawn very early during the acute stage of infection may have *Toxoplasma* IgG levels below 9 IU/mL. The

Toxoplasma IgG assay should not be used alone to diagnose recent *Toxoplasma gondii* infection. Results should be considered in conjunction with clinical presentation, patient history, and other laboratory findings.

Results should be interpreted with caution in HIV-positive patients, patients receiving immunosuppressive therapy, or individuals with other disorders leading to immunosuppression.

Heterophile antibodies in the patient samples may interfere with the assay performance.

As with any low prevalence analyte, there is the increased possibility that a positive result may actually be false, reducing the assay's positive predictive value. Per the Public Health Advisory (7/25/1997), the FDA suggests that sera found to be positive for *Toxoplasma gondii* IgM antibodies should be submitted to a *Toxoplasma* reference laboratory.

IgG is not useful for diagnosing infection in infants younger than 6 months of age. IgG antibodies in this age group usually are the result of passive transfer from the mother.

The performance characteristics of this assay have not been evaluated in immunocompromised individuals and have not been established for cord blood or for testing of neonates.

Clinical Reference

1. Tenter AM, Heckeroth AR, Weiss LM: *Toxoplasma gondii*: from animals to humans. Int J Parasitol 2000;30(12-13):1217-1258
2. Jones JL, Kruszon-Moran D, Rivera HN, et al: *Toxoplasma gondii* seroprevalence in the United States 2009-2010 and comparison with the past two decades. Am J Trop Med Hyg. 2014;90(6):1135-1139
3. Wang ZD, Liu, HH, Ma ZX, et al: *Toxoplasma gondii* infection in immunocompromised patients: A systematic review and Meta-Analysis. Front Microbiol. 2017;8:389
4. Wong SY, Remington JS: Toxoplasmosis in pregnancy. Clin Infect Dis 1994;18(6):853-861

Performance

Method Description

The BioPlex 2200 *Toxoplasma gondii* IgM and IgG assays use multiplex flow immunoassay technology. Briefly, *Toxoplasma* antigen-coated fluorescent beads are mixed with an aliquot of patient sample and sample diluted and incubated at 37 degrees C. During this time IgM and IgG anti-*Toxoplasma* antibodies in the specimen will bind to the *Toxoplasma* antigen on the beads. After a wash cycle, a fluorescently labeled antihuman IgM- and IgG-antibody conjugate is added to the mixture and incubated at 37 degrees C. Following a wash step to remove unbound conjugate, the bead mixture is passed through a detector that identifies the bead based on dye fluorescence and determines the amount of antibody captured by the antigen based on fluorescence of the antihuman-IgG conjugate. Raw data is calculated in relative fluorescence intensity and is converted to an antibody index for interpretation for IgM and an IU/mL for IgG. For IgM, antibody index (AI) values of 0.8 and below are considered negative. AI values of 0.9 and 1.0 are equivocal. AI values of 1.1 and above are considered positive. For IgG, IU/mL values of 9 and below are considered negative. IU/mL values of 10 and 11 are equivocal. IU/mL values of 12 and above are considered positive. Three additional dyed beads, an internal standard bead, a serum verification bead, and a reagent black bead are present in each reaction mixture to verify detector response, the addition of serum to the reaction vessel and the absence of significant nonspecific binding in serum, respectively. (Package inserts: BioPlex 2200 System, ToRC IgG and ToRC IgM, Bio-Rad Laboratories, Clinical Diagnostics Group, Hercules, CA 8/2017)

PDF Report

No

Day(s) and Time(s) Test Performed

Monday through Friday, 9 a.m.

Analytic Time

Same day/1 day

Maximum Laboratory Time

3 days

Specimen Retention Time

14 days

Performing Laboratory Location

Rochester

Fees and Codes**Fees**

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their Regional Manager. For assistance, contact [Customer Service](#).

Test Classification

This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

86778-Toxoplasma IgM

86777-Toxoplasma IgG

LOINC® Information

Test ID	Test Order Name	Order LOINC Value
TXMGP	Toxoplasma Ab, IgM and IgG, S	88746-3

Result ID	Test Result Name	Result LOINC Value
TOXG	Toxoplasma Ab, IgG, S	40677-7
TXM	Toxoplasma Ab, IgM, S	40678-5
DEXG6	Toxoplasma IgG Value	8039-0